TP53 and neuroendocrine carcinoma: Moreover, based on data in cases with spatial and/or temporal heterogeneity, this study proposes an evolutionary model from clones of lower aggressivity through the accumulation of “neuroendocrine carcinoma-like” genetic alterations, such as TP53/RB1 alterations.